Phase 3 Eating Disorders Trial, Recruiting NCT06413433 Sponsor: Axsome Therapeutics, Inc. Condition: Eating Disorders
Back to Eating Disorders

Phase 3 Eating Disorders Trial, Recruiting

NCT06413433
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Binge Eating Disorder (BED) based on standard medical diagnostic guidelines (DSM-5).
  • People who are willing and able to give written consent to take part before any study procedures begin.
  • People who are male or female, aged between 18 and 55 years old (inclusive).

Who may not be able to join:

  • People who have previously taken a medication called solriamfetol (also known as Sunosi), whether through another clinical study or via a prescription.
  • People who are unable to follow the study procedures as required.
  • People whose doctor or the trial investigator considers them medically unsuitable for participation in this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 212-332-5061

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Axsome Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
26 April 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from Baseline to Week 12 in number of binge eating episodes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov